Media Center
A multimedia mosaic of moments at GIST
GIST Excellence
AnyGen Co., Ltd., is the first company by a GIST professor to be listed on KOSDAQ
- 엘리스 리
- REG_DATE : 2016.12.12
- HIT : 1224
AnyGen Co., Ltd., is the first company
by a GIST professor to be listed on KOSDAQ
The induction ceremony was held on the 7th at the
Korea Exchange in Yeouido, Seoul. Professor Jae Il. Kim of GIST
□ AnyGen, a company specializing in the development of peptide biomaterials, was listed on the KOSDAQ for the first time as a company founded by a Gwangju Institute of Science and Technology (GIST) professor.
□ KOSDAQ Market Headquarters held an induction ceremony for AnyGen"s new KOSDAQ market listing at the Seoul office building.
□ AnyGen received a lot of attention from investors, with a final competition rate of 812.5 to 1 in the initial public offer (IPO).
∘ AnyGen said, "The total subscription margin of KRW 1.23 trillion was collected from the general subscription agreement that was held from November 28 to 29. We are pleased to announce that we are the only drug maker in Korea to have good manufacturing practice (GMP) certification."
□ AnyGen is a start-up company established in 2000 by Professor Jae Il. Kim of the GIST School of Life Sciences. He has been working on core technologies for the development of peptide biomaterials and has secured intellectual property rights and R & D know-how.
∘ As a result, the company succeeded in localizing peptide biomaterials, which had been dependent on 100% imports, for the first time in Korea by establishing EU-GMP quality production facilities in EU.
□ AnyGen plans to maximize its production capacity by investing most of its IPO funding in factory construction and by actively enter overseas markets such as India, China, and the United States. In addition, Any Gen is conducting clinical phase 1 clinical trial of AGM-130, a new breast cancer drug for cancer patients who failed standard therapy, and is moving toward technology transfer in the second half of 2017.
AnyGen CEO Jae Il. Kim said, "With the establishment of the second GMP plant, we will develop into one of the world"s top three peptide manufacturing company with global competitiveness within the next five years. I will do our best in leading this company to achieve this result."